178 related articles for article (PubMed ID: 38368200)
1. Navigating uncharted waters: long-term implications of GLP-1 agonist use.
Sher T; Sujka J
Surg Obes Relat Dis; 2024 May; 20(5):499-500. PubMed ID: 38368200
[No Abstract] [Full Text] [Related]
2. New Injectable Agents for the Treatment of Type 2 Diabetes Part 2-Glucagon-Like Peptide-1 (GLP-1) Agonists.
George C; Byun A; Howard-Thompson A
Am J Med; 2018 Nov; 131(11):1304-1306. PubMed ID: 29969616
[TBL] [Abstract][Full Text] [Related]
3. GLP-1 Agonists for Obesity-A New Recipe for Success?
Mozaffarian D
JAMA; 2024 Mar; 331(12):1007-1008. PubMed ID: 38421659
[TBL] [Abstract][Full Text] [Related]
4. Insulin and glucagon-like peptide receptor agonist (GLP 1 RA) combinations.
Kalra S
J Pak Med Assoc; 2014 Mar; 64(3):359-61. PubMed ID: 24864619
[TBL] [Abstract][Full Text] [Related]
5. Glucagon like peptide-1 and its receptor agonists: Their roles in management of Type 2 diabetes mellitus.
Gupta A; Jelinek HF; Al-Aubaidy H
Diabetes Metab Syndr; 2017; 11(3):225-230. PubMed ID: 27884496
[TBL] [Abstract][Full Text] [Related]
6. DR10601, a novel recombinant long-acting dual glucagon-like peptide-1 and glucagon receptor agonist for the treatment of obesity and type 2 diabetes mellitus.
Wang W; Wen X; Duan W; Wang X; Chen Y; Dong J; Yang Z; Fang J; Zhou Z; Yao G; Fang Y; Huang Y
J Endocrinol Invest; 2020 May; 43(5):653-662. PubMed ID: 31786794
[TBL] [Abstract][Full Text] [Related]
7. [GLP-1 agonists: an overview].
Hinneburg I
Med Monatsschr Pharm; 2013 Jul; 36(7):246-51. PubMed ID: 23898602
[TBL] [Abstract][Full Text] [Related]
8. Exploring the Need for Sustained GLP-1 Agonist Therapy: a Perspective on Weight Regain After Bariatric Surgery.
Chang PC; Huang YW; Huang CK; Chang TW
Obes Surg; 2024 Jun; 34(6):2259-2260. PubMed ID: 38619774
[No Abstract] [Full Text] [Related]
9. Improving glucagon-like peptide-1 dynamics in patients with type 2 diabetes mellitus.
Freeman JS
J Am Osteopath Assoc; 2012 Jan; 112(1 Suppl 1):S2-6. PubMed ID: 22267300
[TBL] [Abstract][Full Text] [Related]
10. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
11. Current issues in GLP-1 receptor agonist therapy for type 2 diabetes.
Bloomgarden ZT; Blonde L; Garber AJ; Wysham CH
Endocr Pract; 2012; 18 Suppl 3():6-26; quiz 27-8. PubMed ID: 23315305
[TBL] [Abstract][Full Text] [Related]
12. A novel antihypertensive effect of exenatide, a GLP-1 agonist.
Dandona P; Chaudhuri A; Dhindsa S
Am J Hypertens; 2010 Mar; 23(3):228. PubMed ID: 20154655
[No Abstract] [Full Text] [Related]
13. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
Bloomgarden ZT; Handelsman Y
Endocr Pract; 2015 Dec; 21(12):1442-4. PubMed ID: 26484408
[No Abstract] [Full Text] [Related]
14. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
Tzefos M; Harris K; Brackett A
Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
[TBL] [Abstract][Full Text] [Related]
15. The current significance and prospects for the use of dual receptor agonism GLP-1/Glucagon.
Spezani R; Mandarim-de-Lacerda CA
Life Sci; 2022 Jan; 288():120188. PubMed ID: 34861287
[TBL] [Abstract][Full Text] [Related]
16. Glucagon-like peptide-1 agonists in the treatment of type 2 diabetes.
Edwards CM
Br J Hosp Med (Lond); 2013 Apr; 74(4):198-201. PubMed ID: 23571389
[No Abstract] [Full Text] [Related]
17. Basal insulin or longacting GLP-1 receptor agonists-making the right choice.
Bloomgarden ZT
Lancet Diabetes Endocrinol; 2014 Jun; 2(6):439-41. PubMed ID: 24731676
[No Abstract] [Full Text] [Related]
18. The value of short- and long-acting glucagon-like peptide-1 agonists in the management of type 2 diabetes mellitus: experience with exenatide.
Guo XH
Curr Med Res Opin; 2016; 32(1):61-76. PubMed ID: 26439329
[TBL] [Abstract][Full Text] [Related]
19. A closer look at diabetes remission after gastric bypass surgery: a case study.
Brakoniecki K; Ren-Fielding C; Laferrère B
Surg Obes Relat Dis; 2013; 9(4):e53-5. PubMed ID: 22921456
[No Abstract] [Full Text] [Related]
20. Cigarette smoking, type 2 diabetes mellitus, and glucagon-like peptide-1 receptor agonists as a potential treatment for smokers with diabetes: An integrative review.
Yammine L; Kosten TR; Pimenova M; Schmitz JM
Diabetes Res Clin Pract; 2019 Mar; 149():78-88. PubMed ID: 30735771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
